Tolerability and efficacy of subcutaneous treprostinil therapy in patients with pulmonary arterial hypertension

This study tested the tolerability/efficacy profile of subcutaneous treprostinil therapy in patients with pulmonary arterial hypertension (PAH). Findings showed good tolerability as well as efficacy of subcutaneous treprostinil therapy in these cases.

Advertisement

Methods

• In this study, consecutive 10 patients with PAH who were treated with subcutaneous treprostinil (age : 39.2 ± 12.4, male 10%, idiopathic/heritable PAH 7, associated PAH 2, pulmonary venous occlusive disease 1) were enrolled.

Results

• Data showed that 5 of 10 patients were converted from intravenous epoprostenol and other 5 patients were not treated with parenteral prostanoid before receiving subcutaneous treprostinil.
• Findings demonstrated that all patients were well–tolerated to subcutaneous treprostinil for full observation period (235 ± 175 days, range 41–574 days).
• As per findings, maintenance dose of treprostinil was 57.6 ± 27.6 ng/kg/min.
• Data also revealed that WHO functional class was significantly improved after introduction of subcutaneous treprostinil (from 2.6 ± 0.7 to 2.2 ± 0.9, P = .04).
• Researchers noted that hemodynamic parameters were also significantly improved in 5 patients newly introduced parenteral prostanoid (from 44.8 ± 1.6 to 36.0 ± 3.7 mmHg in mean pulmonary artery pressure, from 8.1 ± 2.4 to 5.0 ± 0.9 wood in pulmonary vascular resistance, P = .02, 0.04, respectively).